Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2008-03-18
2008-03-18
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C540S542000
Reexamination Certificate
active
10969715
ABSTRACT:
The present invention provides methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl}phosphonic acid, and esters thereof.
REFERENCES:
patent: 4390701 (1983-06-01), Algieri et al.
patent: 5124319 (1992-06-01), Baudy et al.
patent: 5168103 (1992-12-01), Kinney et al.
patent: 5212291 (1993-05-01), Murdock et al.
patent: 5240946 (1993-08-01), Kinney et al.
patent: 5583123 (1996-12-01), Lombaert et al.
patent: 5593659 (1997-01-01), Winchell et al.
patent: 5595983 (1997-01-01), Watkins et al.
patent: 5602115 (1997-02-01), Nugent et al.
patent: 5708152 (1998-01-01), Lohmann et al.
patent: 5990307 (1999-11-01), Asselin et al.
patent: 6011168 (2000-01-01), Asselin et al.
patent: 2003/0114444 (2003-06-01), Brandt et al.
patent: 2004/0082543 (2004-04-01), Cheung
patent: 2005/0004079 (2005-01-01), Benjamin et al.
patent: 2005/0004080 (2005-01-01), Baudy et al.
patent: 2005/0142192 (2005-06-01), Benjamin et al.
patent: 2006/0079679 (2006-04-01), Benjamin et al.
patent: 1518660 (1969-08-01), None
patent: 0 496 561 (1992-07-01), None
patent: 0 778 023 (1997-06-01), None
patent: 994 107 (2000-04-01), None
patent: WO 98/15542 (1998-04-01), None
patent: WO 99/06417 (1999-02-01), None
patent: WO 99/64041 (1999-12-01), None
patent: WO 03/031416 (2003-04-01), None
patent: WO 2004/039371 (2004-05-01), None
patent: WO 2004/091633 (2004-10-01), None
patent: WO 2004/092189 (2004-10-01), None
B. Engelsen, “Neurotransmitter glutamate: its clinical importance”, Acta Neurol Scand. (1986) Nov.;74(5):337-55.
Boast, et al., “The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils”, Brain Research, 442 (1998) 345-348.
Schmutz, M. et al.,Abs. Soc. Neurosci. 1988, 14, 864.
J.C.Watkins, “Excitatory Amino Acid Transmitters”, Ann. Rev. Pharmacol. Toxicol. (1981) 21:165-204.
Turski, et al., “Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists”, (Jan. 31, 1991), Nature vol. 349:414-418.
Lehmann, et al., “CPP, a Selective N-Methyl-D-Aspartate (NMDA)-Type Receptor Antagonist: Characterization In Vitro and In Vivo”, The Journal of Pharmacology and Experimental Therapeutics, vol. 240, No. 3:737-746, 1987.
Choi, “Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage”, Trends Neurosci. Oct. 1988;11(10):465-9.
Maragos et al., “Glutamate dysfunction in Alzheimer's disease; an hypothesis”, TINS (Feb. 1987[10]):65-68.
Lehmann, et al. “CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist.” J Pharmacol Exp Ther. Jul. 1988;246(1):65-75.
Johnson, et al., “Excitatory amino acid neurotransmission.”, J Med Chem. Nov. 1988;31(11):2057-66.
Morita, et al., “A convenient Dealkylation of Dialkyl Phosphonates by Chlorotrimethylsilane in the Presence of Sodium Iodide”, Tetrahedron Letters No. 28, pp. 2523-2526, 1978.
Vogtle, et al., “Quadratsaure und Oxalsaure als Bausteine neuer Kronenetheramine und Cryptanden”, Liebigs Ann. Chem. (1977) pp. 1698-1706.
Tietze et al., “Squaric acid diethyl ester: a new coupling reagent for the formation of drug biopolymer conjugates. Synthesis of squaric acid ester amides & diamides” (1991) Inst. Org. Chem. (Abstract only).
Chenard, et al., “A unified approach to systematic isosteric substitutions for acidic groups and application to NMDA antagonists related to 2-amino-7-phosphonoheptanoate.”, J Med Chem. Mar. 1990;33(3):1077-83.
23- Allphatics, 1991, 114, 717, Abs. No. 246836q.
Childers et al., “Neuroprotectant Competitive NMDA Antagonist” Drugs of the Future 2002, 27(7):633-638.
Kinney et al., “Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral alpha-amino acid bioisostere.” J Med Chem. Jan. 15, 1998;41(2):236-46.
Kinney et al., “Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phophonopentanoic acid yields unique 3,4-diamino-3-cyclobutene-1,2-dione containing NMDA antagonists.” J Med Chem. Dec. 11, 1992;35(25):4720-6.
Baudy et al., “Design, synthesis, SAR, and biological evaluation of highly potent benzimidazole-spaced phosphono-alpha-amino acid competitive NMDA antagonists of the AP-6 type.” J Med Chem. May 10, 2001;44(10):1516-29.
Baudy et al. “Potent quinoxaline-spaced phosphono alpha-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation.” J Med Chem. Feb. 5, 1993;36(3):331-42.
Swahn et al., “New Heteroacyl-Spaced phosphono a-amino acids are competitive NMDA antagonists with analgesic activity”, Bioorganic & Medicinal Chemistry Letters, 1996: pp. 1635-1640.
Schmutz et al., “Selfotel (CGS19755)” reference in 1997 Academic Press publication on Excitatory Amino Acids—Clinical Results With Antagonists edited by P.L. Herrling.
Boyd, et al. “Reaction of dehydrodithizone with tetraphenylcyclopentadienone. X-Ray crystal structures of a stable 1,5-dipole, azobenzeneN-(cis-3a,6a-dihydro-4-oxo-3a,5,6,6a-tetraphenyl-4H-cyclopentathiazol-2-yl)-imide, and ofcis-3a,6a-dihydro-3a,5,6,6a-tetraphenyl-2-phenylazo-4H-cyclopentathiazol-4-one” J.C.S. Perkin (1977) pp. 965-971.
Olah, et al., “Iodotrimethylsilane-A Versatile Synthetic Reagent” (1982) Tetrahedron vol. 38;2225-2277.
Derwent World Patent Index record for DE 1518660, 1969.
Abou-Gharbia, Magid, “Optimization of natural procedures leads: discovery of Mylotarg, CCI-779 and GAR-936”, Biodiversity, (Proc. IUPAC Int. Conf.), 3rd, 2002, , Abstract.
Liu Weiguo
Shi Xinxu
Vid Galina
Wilk Bogdan K.
Coleman Brenda
Renda Barbara
Silver Joel
Straher Michael P.
Wyeth
LandOfFree
Methods for the preparation of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the preparation of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the preparation of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3911030